CorneaGen provides high-quality corneal transplant tissue and patient-specific laser-cut tissue inlays, gamma-irradiated for sterility and stability, to enhance vision and comfort for patients with corneal disease. The company also develops specialized surgical instruments, such as the EndoSerter®-PL and Geuder Pre-Loaded Glass Cannula, to improve surgical outcomes for ophthalmologists.

Equinox develops a medical device that utilizes micro-invasive surgical techniques to lower intraocular pressure in glaucoma patients. This technology aims to prevent vision loss associated with progressive eye diseases by providing a more effective and less invasive treatment option.

Tarsus Pharmaceuticals develops targeted therapies for diseases with high unmet medical needs, including the first FDA-approved treatment for Demodex blepharitis, XDEMVY® (lotilaner ophthalmic solution) 0.25%. The company is advancing a robust pipeline of investigational treatments for conditions such as papulopustular rosacea and Lyme disease, addressing significant gaps in available therapies.

The startup develops ophthalmic drug candidates specifically targeting glaucoma, utilizing advanced medication delivery systems to enhance patient safety and adherence. Their approach aims to transform established eye medications into effective therapies, paving the way for future applications across various ocular conditions.